This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: N04.6 (congenital nephrotic syndrome with dense deposit disease / membranoproliferative glomerulonephritis type 2) | Special Copayment Reduction: V263 (rare disease) |
| B. Synonyms | Congenital nephrotic syndrome with dense deposit disease | Congenital nephrotic syndrome with membranoproliferative glomerulonephritis, type 2 |
| C. Adult onset | Likelihood of first onset in adulthood low — DDD is relatively common in children and adolescents, and infantile onset is not uncommonly reported. Some heterozygous CFH variant carriers may remain asymptomatic into adulthood, but registration under the congenital classification (N04.6) presupposes onset within the first year of life. |
| 1. History | 1960s: ribbon-like dense deposits within the GBM discovered on electron microscopy → classified as MPGN type 2 → renamed DDD in 2012; incorporated into the C3 glomerulopathy classification system |
| 2. Causes | Dysregulation of the alternative complement pathway: CFH variants/deficiency, C3 gain-of-function variants, production of anti-C3b antibodies (C3 nephritic factor, C3NeF); rarely CFI, CD46 variants |
| 3. Genetics | CFH (1q32.2): AR or heterozygous; C3 (19p13.3): gain-of-function AD; CFI: AR; C3NeF is an acquired autoantibody but has a genetic background (CFHR1 deletion) |
| 4. General epidemiology | DDD prevalence about 1–2 per million; about 20–30% of all C3 glomerulopathy; more common in children and adolescents, and infantile onset has also been reported |
| 5. Pathophysiology | Persistent activation of C3 convertase (C3bBb) → ribbon-like continuous deposition of C3b polymers within the GBM (finding unique to DDD) → podocyte and endothelial cell injury by complement activation products → proteinuria |
| 6. Symptoms | Hematuria + proteinuria (possibly nephrotic range) + low C3; normal C4; possible macular degeneration (drusen-like deposits, with progression); hypertension |
| 7. Signs | Ribbon-like continuous dense deposits within the GBM on electron microscopy (DDD pathologic criterion); isolated C3 deposition on immunofluorescence; serum complement with low C3 and normal C4 |
| 8. Screening | Monitoring of complement levels (C3, C4); C3NeF, CFH antibodies, complement gene panel; retinal examination (early detection of drusen) |
| 9. Diagnosis | Biopsy (ribbon-like deposits on electron microscopy required), C3NeF, complement gene panel; ophthalmologic examination |
| 10. Treatment | Eculizumab (complement C5 inhibition); MMF; plasma exchange (in CFH deficiency); ACE inhibitors/ARBs; kidney transplantation (high recurrence risk) |
| 11. Prognosis | ESRD within 10 years in about 50%; post-transplant recurrence 90%; risk of macular degeneration; variable prognosis in C3NeF-positive patients |
| 12. Prevention | Genetic counseling for complement gene variants; early initiation of eculizumab; meningococcal vaccination; regular retinal examination |
| 13. References | 10 key references (with PMID or DOI) |
Dense deposit disease (DDD) is a glomerular disease with the distinctive histopathologic feature of ribbon-like, continuous, highly dense (osmophilic) electron-dense deposits within the glomerular basement membrane (GBM) on electron microscopy. In the early 1960s, Berger and Galle, Habib, and others described these characteristic ribbon-like intramembranous deposits on electron microscopy and proposed it as an independent disease distinct from other types of MPGN. Later, in the 1970s–80s, it was called MPGN type 2 (or dense deposit disease) and included within the MPGN classification system.
It was in the late 1970s that the pathogenic mechanism of DDD was clearly shown to be persistent activation of the alternative complement pathway rather than immune complexes. C3 nephritic factor (C3NeF) is an autoantibody that stabilizes C3 convertase (C3bBb) and is found in about 60–80% of DDD patients. It was established as central to DDD pathology that the presence of C3NeF persistently activates C3 convertase, causing low serum C3 and glomerular C3 deposition.
In the 2012 MPGN reclassification proposed by Sethi and Fervenza, DDD was incorporated as a type of C3 glomerulopathy, and ribbon-like intramembranous deposits on electron microscopy were recognized as the diagnostic gold standard. In addition, as CFH, CFI, and C3 gene variants were identified as genetic causes of DDD, DDD has come to be understood as a disease in which hereditary and acquired (C3NeF autoantibody) causes act in combination.
The core cause of DDD is dysregulation of the alternative complement pathway, involving the following mechanisms.
C3 nephritic factor (C3NeF): an autoantibody that binds to C3 convertase (C3bBb) and protects it from degradation; it is positive in about 60–80% of DDD patients. Because of C3NeF, C3 convertase is persistently activated, serum C3 is depleted (low C3), and C3 breakdown products are continuously deposited in the glomeruli. C3NeF is an acquired autoantibody, but its production is promoted when there is a genetic background such as CFHR1 deletion.
CFH (complement factor H) variants or deficiency: complete CFH deficiency due to homozygous CFH variants results in persistent activation of C3 convertase, profoundly low serum C3, and DDD or aHUS. Heterozygous variants show diverse phenotypes with incomplete penetrance.
C3 gain-of-function variants: gain-of-function variants of the C3 gene prevent C3b from being inactivated by CFH, persistently activating C3 convertase. They show an autosomal dominant inheritance pattern and can cause pediatric-onset C3 glomerulopathy/DDD.
CFI (complement factor I) variants: deficiency or dysfunction of CFI, which is required for C3b inactivation, also causes alternative pathway hyperactivation and DDD/C3 glomerulopathy.
DDD is a disease in which hereditary (CFH, CFI, C3 variants) and acquired (C3NeF autoantibody) causes are involved in combination.
CFH (1q32.2): complete deficiency → AR inheritance, infantile-onset DDD/aHUS. Heterozygous loss-of-function variants → incomplete penetrance, variable age of onset. In addition to the CFH gene, rearrangements/deletions of the adjacent CFHR1–CFHR5 genes promote production of anti-CFH antibodies, producing an effect similar to C3NeF.
C3 (19p13.3): gain-of-function missense variants → AD inheritance → C3 convertase hyperactivation → DDD or C3GN. Examples: gain-of-function variants such as p.K155Q and p.I734T.
CFI (4q25): with AR variants, failure of C3b inactivation → complement consumption → DDD/C3GN.
Genetic testing strategy: C3NeF and anti-CFH antibodies are measured first; if negative, a gene panel for CFH, CFI, C3, CFHR1–5, and MCP/CD46 or WES is performed. Genetic diagnosis bears directly on decisions about eculizumab treatment, family counseling, and kidney transplantation strategy (combined liver-kidney transplantation considered in complete CFH deficiency).
DDD is a very rare glomerular disease, with a reported prevalence of about 1–2 per million in adult and pediatric populations. DDD accounts for about 20–30% of all C3 glomerulopathy (DDD + C3GN), and C3GN is more common. It tends to occur relatively more often in children and adolescents than in adults; the mean age of onset is reported as about 10–20 years, but infantile onset is also not uncommonly reported.
There is no or only a slight sex difference, and no clear ethnic specificity. Founder variants for complete CFH deficiency (AR) have been reported in some countries such as Finland, but most CFH variants are sporadic. The number of patients registered with DDD (N04.6) in Korea is very small, and they are managed under Special Copayment Reduction code V263. There are no epidemiological studies of DDD alone in Korea, but for complement glomerulopathies as a whole, a few dozen cases have been reported at pediatric nephrology centers. In Western cohorts, C3NeF is positive in about 30–70% of DDD patients, and the proportion of hereditary causes tends to be higher in children than in adults.
The core of DDD pathophysiology is persistent activation of C3 convertase (C3bBb) due to dysregulation of the alternative complement pathway and deposition of C3b polymers within the GBM.
Hyperactivation of the C3 alternative pathway: normally, C3 reacts spontaneously with water molecules to generate small amounts of C3b, which is continuously inactivated by CFH and CFI. When CFH deficiency or stabilization of C3 convertase by C3NeF occurs, C3b generation is amplified and serum C3 is rapidly depleted, resulting in hypocomplementemia (low C3, normal C4).
Deposition of C3b polymers within the GBM: excess C3b and its breakdown products (iC3b, C3d, C3dg) are abnormally deposited within the GBM. In DDD, these C3 deposits accumulate within the GBM as ribbon-like, continuous, highly dense material, which is the characteristic 'dense deposit' finding on electron microscopy. Because immune complexes other than C3 (IgG, IgM) are not deposited, isolated C3 deposition on immunofluorescence is characteristic of DDD.
Podocyte and glomerular injury: persistent C3 activation products (C3a: inflammation, C5a: neutrophil recruitment, C5b-9: cell injury by MAC) damage podocytes and endothelial cells, causing foot process effacement and massive proteinuria. Similar deposits also occur in the macula, where subretinal drusen-like deposits may form, which can appear as a DDD-like form of age-related macular degeneration (AMD).
The clinical symptoms of DDD present as a mixed pattern of nephrotic-range proteinuria and hematuria, and complement abnormalities are characteristic.
Renal symptoms: nephrotic-range proteinuria (UPCR ≥ 2.0 mg/mg; in some it appears in the non-nephrotic range) and microscopic or gross hematuria present simultaneously. Hypoalbuminemia, edema, and hyperlipidemia appear as nephrotic components. Hypertension is a common accompanying finding. Acute kidney injury (AKI) may occur early, and renal function declines gradually over a chronic course.
Complement abnormalities: marked reduction of serum C3 (possibly to less than 30% of normal) with normal C4 is the characteristic serum finding of DDD. Low C3 is used both as a diagnostic clue to DDD and as an indicator of disease activity.
Ophthalmologic findings: as macular deposits (drusen-like) progress, symptoms of macular degeneration (decreased vision, metamorphopsia) may appear. This is the reason regular ophthalmologic examination is needed, especially in patients with a long-term course.
Systemic findings: rarely, partial lipodystrophy has been reported to accompany DDD in C3NeF-positive patients. This is explained by local complement activation in subcutaneous adipose tissue.
Physical examination: edema, elevated blood pressure, hematuria (urine discoloration). With partial lipodystrophy, loss of subcutaneous fat in the upper limbs and face is observed. Macular drusen-like deposits may be identified on ophthalmologic examination.
Laboratory findings: urine: proteinuria (2–4+), hematuria (2–3+), red blood cell casts. Low serum C3 (essential finding), normal C4. C3NeF positive (about 60–80%). Anti-CFH antibodies, presence of CFHR1 deletion. Low serum albumin (with nephrotic syndrome), hyperlipidemia. Elevated creatinine and BUN (with decreased renal function).
Kidney biopsy findings: light microscopy: MPGN pattern (GBM double contours, mesangial expansion) or mesangial proliferative pattern. Immunofluorescence: isolated C3 deposition (continuous/granular along the GBM). IgG, IgM negative or minimal. Electron microscopy: ribbon-like, continuous, highly dense electron-dense deposits within the GBM are the pathologic gold standard finding of DDD. Podocyte foot process effacement and mesangial deposits are also observed.
General population screening is unnecessary. A systematic approach is needed for clinical suspicion and high-risk families.
Testing based on clinical suspicion: in infants and children with the combination of hematuria + proteinuria + low C3 (normal C4), or nephrotic-range proteinuria + complement abnormalities, the possibility of DDD is considered immediately, and C3NeF, anti-CFH antibody, and complement gene panel tests are performed.
Monitoring of high-risk families: newborns from families with confirmed CFH, CFI, or C3 gene variants undergo urine protein and hematuria testing along with regular monitoring of complement levels (C3, C4). In newborns with confirmed gene variants, meningococcal vaccination is completed early and preparations are made for eculizumab.
Ophthalmologic examination: at the diagnosis of DDD, a baseline ophthalmologic examination (macular examination, OCT, fluorescein angiography) is performed, followed by ophthalmologic follow-up every year or every 2 years for surveillance of macular degeneration.
The key to confirming DDD is identification of ribbon-like continuous dense deposits within the GBM on electron microscopy.
Clinical and laboratory criteria: the combination of proteinuria + hematuria + low C3 (normal C4) + C3NeF positivity (60–80%) strongly suggests DDD. Even if C3NeF is negative, biopsy is performed if the clinical findings are consistent.
Kidney biopsy: MPGN or mesangial proliferative pattern confirmed on light microscopy. Isolated C3 deposition on immunofluorescence (IgG, IgM negative) is the criterion for C3 glomerulopathy. Ribbon-like dense deposits within the GBM on electron microscopy are the confirmatory criterion for DDD (distinction from C3GN: in C3GN, subendothelial and mesangial deposits are scattered and not ribbon-like). C3d immunohistochemistry in tissue confirms deposition of C3 breakdown products.
Complement tests: serum C3, C4, CH50, AH50. C3NeF (C3 convertase autoantibody). Anti-CFH antibodies, CFHR1 deletion (MLPA or WGS). Complement gene panel (CFH, CFI, C3, MCP/CD46, CFHR1–5). WES or WGS.
Differential diagnosis: C3GN (no ribbon-like deposits on electron microscopy), MPGN type 1 (Ig + C3 on immunofluorescence, subendothelial deposits), lupus nephritis (ANA, anti-dsDNA positive), PSGN (onset after acute infection, self-limited).
Standardized evidence-based treatment for DDD is currently limited, and treatment centers mainly on complement inhibition and supportive care.
Eculizumab: a C5 inhibitor whose efficacy is established in aHUS, but limited efficacy has been reported in DDD. Reduced proteinuria and stabilization of renal function were observed in some patients, but systematic evidence is lacking. Prior meningococcal vaccination (MenACWY, MenB 2 or more doses) is mandatory when using eculizumab. Clinical trials of new complement inhibitors such as pegcetacoplan (a C3 inhibitor) are under way in DDD patients who do not respond to eculizumab.
MMF (mycophenolate mofetil): some clinical studies report that MMF is effective in reducing proteinuria, but the level of evidence is low. It is used in combination with steroids or alone. In C3NeF-positive patients, MMF is expected to suppress autoantibody production.
Plasma therapy in CFH deficiency: in patients with complete (homozygous) CFH deficiency, supplementing CFH with fresh frozen plasma (FFP) or plasma exchange can temporarily normalize complement levels and improve renal findings.
Kidney transplantation: upon progression to ESRD, kidney transplantation is the only definitive treatment. However, the post-transplant recurrence rate in DDD is very high at about 80–90%, so identifying and controlling the cause of the complement abnormality before transplantation is important. In patients with complete CFH deficiency, simultaneous liver-kidney transplantation (CFH is synthesized mainly in the liver) is considered as a strategy to prevent recurrence.
DDD is known to have a poor long-term prognosis. In adult cohorts, about 50% of patients progress to ESRD within 10 years of diagnosis, and progression may be faster in pediatric onset.
Renal prognosis: C3NeF positivity, reduced GFR, extensive crescent formation (crescents), and the degree of tubulointerstitial fibrosis are poor prognostic factors. In patients who respond to complement inhibition therapy, the rate of renal function decline may slow. Because the post-transplant recurrence rate is very high at 80–90%, active complement monitoring and treatment are needed even after transplantation.
Ophthalmologic prognosis: as macular drusen-like deposits progress, decreased vision and macular degeneration may develop, showing a clinical course similar to age-related macular degeneration (AMD). Regular ophthalmologic follow-up is essential.
Partial lipodystrophy: when associated with C3NeF, loss of subcutaneous fat may progress, and this is difficult to reverse with treatment. In some DDD patients, this finding may appear before the onset of renal disease, serving as a clue to early diagnosis.
Prevention of DDD consists mainly of genetic counseling, early detection of complement gene variants, and prevention of complications.
Genetic counseling and genetic testing: genetic counseling and prenatal/preimplantation genetic testing are offered to families with confirmed CFH, CFI, or C3 variants. In families with AR inheritance (complete CFH or CFI deficiency), it is clearly explained that the recurrence risk is 25%. Newborns carrying variants require early complement level monitoring and preparation for rapid administration of eculizumab.
Meningococcal vaccination: in all patients for whom eculizumab is planned or in whom complement abnormalities have been confirmed, the quadrivalent meningococcal vaccine (MenACWY) and serogroup B meningococcal vaccine (MenB) are given at least 2 weeks before eculizumab administration. Prophylactic penicillin is given concurrently during eculizumab maintenance.
Ophthalmologic surveillance: from the diagnosis of DDD, regular ophthalmologic examinations (every 1–2 years) are performed to detect macular degeneration early and prepare for anti-VEGF therapy, etc. Ophthalmologic follow-up is maintained even after kidney transplantation.